Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.

As all STCs for pediatric EoE treatment were used off-label (given the absence of approved STCs for children with EoE aged <11 years), there may be significant heterogeneity between individual doses and treatment potency based on the formulation and delivery mechanism.

also in 13,097 other papers

In conclusion, higher-exposure dupilumab was effective and tolerated in pediatric patients aged 1–11 years with EoE with prior STC use and in patients with prior IRIC to STCs, as demonstrated by nominally significant improvements in histologic and endoscopic outcomes, and numerically improved EoE symptomology in these subgroups.

also in 7,732 other papers